
Carina Blomström-Lundqvist

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8524754/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
2	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	0.7	1,360
3	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	0.7	635
4	The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes. European Heart Journal, 2017, 38, 2995-3005.	1.0	339
5	2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS, Europace, 2018, 20, 1217-1217, European Heart Rhythm Association (EHRA) international consensus document on how to prevent,	0.7	243
6	diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	0.7	216
7	Association for Cardio. Europace, 2020, 22, 515-549. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2019, 321, 1059. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial	3.8	214
8	fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care	0.7	209
9	(ACCA) endorsed by the Heart Rhythm So. Europace, 2019, 21, 192-193 Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. European Heart Journal, 2017, 38, ehw564.	1.0	151
10	A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). European Heart Journal, 2007, 28, 2902-2908.	1.0	136
11	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	0.7	121
12	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace, 2017, 19, euw141.	0.7	120
13	diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	1.0	120
14	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ ³ n Cardiaca y Electrofisiologia (SOLAECE). Europace, 2017, 19, 465-511.	0.7	118
15	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. Thrombosis and Haemostasis, 2021, 121, 270-278 European Heart Rhythm Association (EHRA) international consensus document on how to prevent,	1.8	118
16	diagnose, and treat cardiac implantable electronic device infectionsâ€"endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	0.6	111
17	Association for Cardio. European Journal of Cardio-thoracic Surgery, 2020, 57, e1-e31. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how?. European Journal of Heart Failure, 2018, 20, 1039-1051.	2.9	107
18	Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial. European Heart Journal, 2015, 36, 2500-2507.	1.0	98

#	Article	IF	CITATIONS
19	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	0.7	95
20	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	0.7	72
21	Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. Europace, 2019, 21, 581-589.	0.7	69
22	Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart, 2019, 105, 244-250.	1.2	67
23	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace. 2019. 21. 1603-1604.	0.7	61
24	Major cardiac and vascular complications after transvenous lead extraction: acute outcome and predictive factors from the ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry. Europace, 2019, 21, 771-780.	0.7	56
25	Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation. JAMA Cardiology, 2017, 2, 146.	3.0	54
26	Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace, 2016, 18, 151-155.	0.7	50
27	Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace, 2016, 18, 463-467.	0.7	49
28	Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association. Europace, 2019, 21, 1270-1279.	0.7	49
29	Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace, 2015, 17, 1596-1600.	0.7	46
30	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace, 2019, 21, 1459-1467.	0.7	45
31	The use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of Cardiovascular Imaging and the European Society of Cardiac Radiology, Europace, 2013, 15, 927-936.	0.7	38
32	Risk stratification of patients undergoing transvenous lead extraction with the ELECTRa Registry Outcome Score (EROS): an ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry analysis. Europace, 2021, 23, 1462-1471.	0.7	38
33	Catheter ablation for atrial fibrillation: results from the first European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA) Part II. Europace, 2015, 17, 1727-1732.	0.7	36
34	In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences. Europace, 2020, 22, 66-73.	0.7	33
35	Management of malfunctioning and recalled pacemaker and defibrillator leads: results of the European Heart Rhythm Association survey. Europace, 2014, 16, 1674-1678.	0.7	32
36	Use of fluoroscopy in clinical electrophysiology in Europe: results of the European Heart Rhythm Association Survey. Europace, 2015, 17, 1149-1152.	0.7	32

IF # ARTICLE CITATIONS Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey. Europace, 2015, 17, 314-317. What are the costs of atrial fibrillation?. Europace, 2011, 13, ii9-ii12. 38 0.7 29 Use of event recorders and loop recorders in clinical practice: results of the European Heart Rhythm 28 Association Survey. Europace, 2014, 16, 1384-1386. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm 40 1.0 28 Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ³n Cardiaca y Electrofisiologia (SOLAECE). European Heart Journal, 2018, 39, ehw455. How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. Europace, 2015, 17, 468-472. How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey. Europace, 2014, 16, 1852-1856. 42 0.7 24 European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace, 2018, 20, 895-896. 24 Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac 44 0.7 23 implantable electronic device infection risk score. Europace, 2021, 23, 1446-1455. European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace, 2015, 17, 137-141. The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa 0.7 22 46 registry subanalysis. Europace, 2020, 22, 1718-1728. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its 0.7 use in atrial fibrillation. Europace, 2019, 21, 1764-1775. European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the 48 0.7 20 European Heart Rhythm Association of the European Society of Cardiology. Europace, 2022, 24, 165-172. Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). Europace, 2016, 18, 778-784. 0.7 Thoracoscopic epicardial left atrial ablation in symptomatic patients with atrial fibrillation. 50 0.7 19 Europace, 2016, 18, 1538-1544. Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?—findings from the ESC CRT Survey II. Europace, 2019, 21, 918-927. Acute and long-term efficacy and safety with a single cryoballoon application as compared with the standard dual application strategy: a prospective randomized study using the second-generation 52 0.7 18 cryoballoon for pulmonary vein isolation in patients with symptomatic atrial fibrillation. Europace, 2018, 20, 1598-1605. Prevention of cardiac implantable electronic device infections: guidelines and conventional 0.7 prophylaxis. Europace, 2021, 23, iv11-iv19. Influence of risk factors in the ESCâ€EHRA EORP atrial fibrillation ablation longâ€term registry. PACE -54 0.5 15 Pacing and Clinical Electrophysiology, 2019, 42, 1365-1373.

ARTICLE IF CITATIONS Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial 1.3 Fibrillation and a Single Additional Stroke Risk Factor. Advances in Therapy, 2017, 34, 357-377. Persistency of left atrial linear lesions after radiofrequency catheter ablation for atrial fibrillation: Data from an invasive followâ€up electrophysiology study. Journal of Cardiovascular 56 0.8 13 Electrophysiology, 2017, 28, 1403-1414. Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace, 2014, 16, 1521-1523. Quality of life is not improved after mitral valve surgery combined with epicardial left atrial cryoablation as compared with mitral valve surgery alone: a substudy of the double blind randomized 58 0.7 12 SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Europace, 2018, 20, f343-f350. Sex-Related Procedural Aspects and Complications in CRT Survey II. JACC: Clinical Electrophysiology, 59 1.3 2019, 5, 1048-1058. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate 60 patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. 0.7 12 Europace, 2022, 24, 721-728. Standards for device implantation and follow-up: personnel, equipment, and facilities: results of the European Heart Rhythm Association Survey. Europace, 2014, 16, 1236-1239. Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation 62 0.7 11 ablation long-term registry. Europace, 2019, 21, 1802-1808. Supraventricular Arrhythmias in Patients with Adult Congenital Heart Disease. Arrhythmia and 1.3 Electrophysiology Review, 2017, 6, 42. Current implantable cardioverter-defibrillator programming in Europe: the results of the European 64 0.7 10 Heart Rhythm Association survey. Europace, 2014, 16, 935-938. Do cardiologists follow the European guidelines for cardiac pacing and resynchronization therapy? 0.7 10 Results of the European Heart Rhythm Association survey. Europace, 2015, 17, 148-151. Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) 66 0.7 10 registry. Europace, 2019, 21, 1876-1889. Impact of renal impairment on atrial fibrillation: ESCâ€EHRA EORPâ€AF Longâ€Term General Registry. European Journal of Clinical Investigation, 2022, 52, e13745. AIMâ€AF: A Physician Survey in the United States and Europe. Journal of the American Heart Association, 68 1.6 10 2022, 11, e023838. Management of patients with ventricular tachycardia in Europe: results of the European Heart 69 Rhythm Association survey. Europace, 2015, 17, 1294-1299. Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESCâ€EHRA Atrial 70 0.5 9 Fibrillation Ablation Longâ€Term Registry. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 313-320. Lead fixation mechanism impacts outcome of transvenous lead extraction: data from the European 71 Lead Extraction ConTRolled Registry. Europace, 2022, 24, 817-827. Clinical impact of antithrombotic therapy in transvenous lead extraction complications: a 72 sub-analysis from the ESC-EORP EHRA ELECTRa (European Lead Extraction ConTRolled) Registry. 0.7 8 Europace, 2019, 21, 1096-1105.

IF # ARTICLE CITATIONS Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the <scp>ATHENA </scp>study. Clinical Cardiology, 2020, 43, 1469-1477. Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. 74 0.7 8 Europace, 2020, 22, 932-938. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity. Expert Opinion on Drug Safety, 2012, 11, 1.0 671-679. Personnel, equipment, and facilities for electrophysiological and catheter ablation procedures in 7 76 0.7 Europe: results of the European Heart Rhythm Association Survey. Europace, 2014, 16, 1078-1082. Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot 0.7 Registries. Europace, 2020, 22, 250-258. How are arrhythmias detected by implanted cardiac devices managed in Europe? Results of the 78 0.7 6 European Heart Rhythm Association Survey. Europace, 2015, 17, 1449-1453. Sex-related differences in atrial fibrillation: can we discern true disparities from biases?. Heart, 2017, 79 <u>103, 979-981</u>. 1.2 Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial 80 0.6 6 Fibrillation: An Appraisal. American Journal of Medicine, 2017, 130, 773-779. Clinical outcome of the 2nd generation cryoballoon for pulmonary vein isolation in patients with persistent atrial fibrillation â€" A sub-study of the randomized trial evaluating single versus dual 0.8 cryoballoon applications. International Journal of Cardiology, 2019, 278, 120-125. Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC 82 0.7 6 EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. Europace, 2021, 23, 49-58. QRS dispersion detected in ARVC patients and healthy gene carriers using 252â€leads body surface mapping: an explorative study of a potential diagnostic tool for arrhythmogenic right ventricular cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1355-1364. Reflections on the usefulness of today's atrial fibrillation ablation procedure endpoints and 84 0.7 6 patient-reported outcomes. Europace, 2022, 24, ii29-ii43. Effect of parasympathetic nerve stimulation on atrial and atrioventricular nodal 0.8 electrophysiológical characteristics. International Journal of Cardiology, 2016, 205, 83-85. Atrial fibrillation burden, episode duration and frequency in relation to quality of life in patients 86 0.6 5 with implantable cardiac monitor. IJC Heart and Vasculature, 2021, 34, 100791. Identifying risk of adverse outcomes in COVID-19 patients via artificial intelligence–powered analysis of 12-lead intake electrocardiogram. Cardiovascular Digital Health Journal, 2022, 3, 62-74. Machine learning–derived major adverse event prediction of patients undergoing transvenous lead extraction: Using the ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry. Heart 88 0.3 5 Rhythm, 2022, 19, 885-893. Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the 1.0 ESC-EHRA EORP-AF Long-Term General Registry. European Journal of Internal Medicine, 2022, 103, 41-49. Short P-Wave Duration Is Associated with Incident Atrial Fibrillation. International Heart Journal, 90 0.5 5 2022, 63, 700-707.

ARTICLE IF CITATIONS # Executive Summary: European Heart Rhythm Association Consensus Document on the Management of 1.3 Supraventricular Arrhythmias. Arrhythmia and Electrophysiology Review, 2016, 5, 210. Left atrial function after epicardial pulmonary vein isolation in patients with atrial fibrillation. 92 4 0.6 Journal of Interventional Cardiac Electrophysiology, 2017, 50, 195-201. Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTRolled ELECTRa registry: is female sex a predictor of complications?. Europace, 2019, 21, 1890-1899. Effects of COVID-19 lockdown strategies on management of atrial fibrillation. European Heart 94 1.0 4 Journal, 2020, 41, 3080-3082. Increase of Ventricular Interval During Atrial Fibrillation by Atrioventricular Node Vagal 2.1 Stimulation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 562-568. Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in 96 Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the 2.9 3 European Heart Rhythm Association. European Journal of Heart Failure, 2019, 21, 690-693. Atrial fibrillation ablation long-term ESC-EHRA EORP AFA LT registry: in-hospital and 1-year follow-up findings in Italy. Journal of Cardiovascular Medicine, 2020, 21, 740-748. 0.6 Repolarisation abnormalities unmasked with a 252â€lead BSM system in patients with ARVC and healthy 98 0.5 3 Gene Carriers. PACE - Pacing and Clinical Electrophysiology, 2022, , . Antibiotic-Eluting Envelopes for the Prevention of Cardiac Implantable Electronic Device Infections: 1.1 Rationale, Efficacy, and Cost-Effectiveness. Frontiers in Cardiovascular Medicine, 2022, 9, 855233. 100 Drug treatment of supraventricular tachycardia. Heart, 2009, 95, 1803-1807. 1.2 9 The results of healthâ€related quality of life assessment depend on the prevailing rhythm at the assessment: Experience from the CAPTAF trial (Catheter Ablation Compared with Pharmacological) Tj ETQq1 1 0.784814 rgB2 /Overld Recent-onset atrial fibrillation: a study exploring the elements of Virchow's triad after 102 2 0.6 cardioversion. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 49-58. Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation 0.8 Ablation long-term (AFA LT) registry. International Journal of Cardiology, 2022, 346, 19-26. Serial Magnetic Resonance Imaging after Electrical Cardioversion of Recent Onset Atrial Fibrillation in Anticoagulant-NaÃ⁻ve Patients – A Prospective Study Exploring Clinically Silent Cerebral Lesions. 104 0.5 2 Journal of Atrial Fibrillation, 2020, 13, 2271. CABANA Trial, another favourable view. European Heart Journal, 2018, 39, 2771-2772. Adenosine usage during AF ablation in Europe and selected long-term findings from the ESC-EHRA EORP Atrial Fibrillation Ablation Long-Term registry. Journal of Interventional Cardiac 106 0.6 1 Electrophysiology, 2021, 60, 395-406. The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa Registry subanalysisâ€"Author's reply. Europace, 2021, 23, 1149-1150. Device infections related to cardiac resynchronization therapy in clinical practice–An analysis of its 108 prevalence, risk factors and routine surveillance at a single center university hospital. Clinical 0.7 1 Cardiology, 2021, 44, 739-747.

#	Article	IF	CITATIONS
109	OUP accepted manuscript. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	1
110	Management of paediatric arrhythmias in Europe: authors' reply. Europace, 2015, 17, 1879.2-1880.	0.7	0
111	EHRA research network surveys: 6 years of EP wires activity. Europace, 2015, 17, 1733-1738.	0.7	0
112	Programmed ventricular stimulation early after myocardial infarction: authors' reply. Europace, 2016, 18, 789.2-790.	0.7	0
113	Atrial fibrillation history impact on catheter ablation outcome. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 759-759.	0.5	0
114	Redefining the Standard for Atrial Fibrillation: A Patient-centric Report. European Cardiology Review, 2021, 16, 1-6.	0.7	0
115	EHRA(European Heart Rhythm Association) EP-Wires Surveys: What Is Common Practice In Device Management?. Journal of Atrial Fibrillation, 2014, 7, 1115.	0.5	0